Obesity Drugs Are a Potential $100 Billion Opportunity by 2030, Goldman Sachs Analysts Say
As the buzz surrounding weight-loss drugs gets ever louder, analysts at Goldman Sachs Group Inc. predict the market for such products could reach $100 billion by 2030, with Eli Lilly & Co. and Novo Nordisk A/S leading the pack.